{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:29:20Z","timestamp":1759177760778,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031A424"],"award-info":[{"award-number":["031A424"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Individualization and patient-specific optimization of treatment is a major goal of modern health care. One way to achieve this goal is the application of high-resolution diagnostics together with the application of targeted therapies. However, the rising number of different treatment modalities also induces new challenges: Whereas randomized clinical trials focus on proving average treatment effects in specific groups of patients, direct conclusions at the individual patient level are problematic. Thus, the identification of the best patient-specific treatment options remains an open question. Systems medicine, specifically mechanistic mathematical models, can substantially support individual treatment optimization. In addition to providing a better general understanding of disease mechanisms and treatment effects, these models allow for an identification of patient-specific parameterizations and, therefore, provide individualized predictions for the effect of different treatment modalities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the following we describe a software framework that facilitates the integration of mathematical models and computer simulations into routine clinical processes to support decision-making. This is achieved by combining standard data management and data exploration tools, with the generation and visualization of mathematical model predictions for treatment options at an individual patient level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>By integrating model results in an audit trail compatible manner into established clinical workflows, our framework has the potential to foster the use of systems-medical approaches in clinical practice. We illustrate the framework application by two use cases from the field of haematological oncology.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12911-020-1039-x","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T18:03:10Z","timestamp":1581357790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology"],"prefix":"10.1186","volume":"20","author":[{"given":"Katja","family":"Hoffmann","sequence":"first","affiliation":[]},{"given":"Katja","family":"Cazemier","sequence":"additional","affiliation":[]},{"given":"Christoph","family":"Baldow","sequence":"additional","affiliation":[]},{"given":"Silvio","family":"Schuster","sequence":"additional","affiliation":[]},{"given":"Yuri","family":"Kheifetz","sequence":"additional","affiliation":[]},{"given":"Sibylle","family":"Schirm","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Horn","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[]},{"given":"Constanze","family":"Volgmann","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Scholz","sequence":"additional","affiliation":[]},{"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Loeffler","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-0608","authenticated-orcid":false,"given":"Ingo","family":"Roeder","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"publisher","unstructured":"Schirm S, Engel C, Loeffler M, Scholz M: A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment. Theor Biol Med Model 2014, 11(1):24.https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/1742-4682-11-24.","DOI":"10.1186\/1742-4682-11-24"},{"key":"1039_CR2","doi-asserted-by":"publisher","unstructured":"Schirm S, Engel C, Loeffler M, Scholz M: Modelling chemotherapy effects on granulopoiesis. BMC Syst Biol 2014, 8(1):138.https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/s12918-014-0138-7.","DOI":"10.1186\/s12918-014-0138-7"},{"key":"1039_CR3","doi-asserted-by":"publisher","unstructured":"Schirm S, Engel C, Loibl S, Loeffler M, Scholz M: Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. J Cancer Res Clin Oncol 2018, 144(2):343\u2013358.https:\/\/doi.org\/https:\/\/doi.org\/10.1007\/s00432-017-2540-1.","DOI":"10.1007\/s00432-017-2540-1"},{"key":"1039_CR4","doi-asserted-by":"publisher","unstructured":"R\u00f6sch K, Scholz M, Hasenclever D: Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma. Leukemia Lymphoma 2016, 57(7):1697\u20131708.https:\/\/doi.org\/https:\/\/doi.org\/10.3109\/10428194.2015.1110746.","DOI":"10.3109\/10428194.2015.1110746"},{"key":"1039_CR5","doi-asserted-by":"publisher","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M: Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006, 12:1181.http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1038\/nm1487.","DOI":"10.1038\/nm1487"},{"issue":"2","key":"1039_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","volume":"121","author":"M Horn","year":"2013","unstructured":"Horn M, Glauche I, M\u00fcller MC, Hehlmann R, Hochhaus A, Loeffler M, Roeder I. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood. 2013;121(2):378\u201384 http:\/\/www.bloodjournal.org\/content\/bloodjournal\/121\/2\/378.full.pdf.","journal-title":"Blood"},{"key":"1039_CR7","unstructured":"Fassoni AC, Baldow C, Roeder I, Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase 3 trial data. Haematologica. 2018; http:\/\/www.haematologica.org\/content\/haematol\/early\/2018\/06\/26\/haematol.2018.194522.full.pdf."},{"key":"1039_CR8","doi-asserted-by":"publisher","unstructured":"Glauche I, Kuhn M, Baldow C, Schulze P, Rothe T, Liebscher H, Roy A, Wang X, Roeder I: Quantitative prediction of long-term molecular response in TKI-treated CML \u2013 lessons from an imatinib versus dasatinib comparison. Sci Rep 2018, 8(1):12330.https:\/\/doi.org\/https:\/\/doi.org\/10.1038\/s41598-018-29923-4.","DOI":"10.1038\/s41598-018-29923-4"},{"key":"1039_CR9","unstructured":"SQL Server 2008 R2 - Online Documentation. https:\/\/www.microsoft.com\/de-de\/download\/details.aspx?id=9071."},{"key":"1039_CR10","unstructured":"PHP 7 - Hypertext Preprocessor. http:\/\/php.net\/."},{"key":"1039_CR11","unstructured":"Chang W, Cheng J, Allaire J, Xie Y, McPherson J: Shiny: Web Application Framework for R. R package version 1.0.0. In.; 2017.https:\/\/CRAN.R-project.org\/package=shiny."},{"key":"1039_CR12","doi-asserted-by":"publisher","unstructured":"Baldow C, Salentin S, Schroeder M, Roeder I, Glauche I: MAGPIE: simplifying access and execution of computational models in the life sciences. PLoS Comput Biol 14(3): e1006083 2018.https:\/\/doi.org\/https:\/\/doi.org\/10.1371\/journal.pcbi.1006083.","DOI":"10.1371\/journal.pcbi.1006083"},{"key":"1039_CR13","unstructured":"Ruby on Rails. https:\/\/rubyonrails.org\/."},{"key":"1039_CR14","unstructured":"Nginx HTTP-Server. https:\/\/nginx.org."},{"key":"1039_CR15","doi-asserted-by":"publisher","unstructured":"Lautenschl\u00e4ger R, Kohlmayer F, Prasser F, Kuhn KA: A generic solution for web-based management of pseudonymized data. BMC Med Informatics Decis Mak 2015.https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/s12911-015-0222-y.","DOI":"10.1186\/s12911-015-0222-y"},{"key":"1039_CR16","unstructured":"Data protection working group of the TMF eV. http:\/\/www.tmf-ev.de\/EnglishSite\/WorkingGroups\/Dataprotectionworkinggroup.aspx."},{"issue":"2","key":"1039_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jtbi.2009.12.032","volume":"264","author":"M Scholz","year":"2010","unstructured":"Scholz M, Gross A, Loeffler M. A biomathematical model of human thrombopoiesis under chemotherapy. J Theor Biol. 2010;264(2):287\u2013300 http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022519310000056.","journal-title":"J Theor Biol"},{"key":"1039_CR18","doi-asserted-by":"publisher","unstructured":"Kheifetz Y, Scholz M: Modeling individual time courses of thrombopoiesis during multi-cyclic chemotherapy. PLoS Comput Biol 2019, 15(3):e1006775.https:\/\/doi.org\/https:\/\/doi.org\/10.1371\/journal.pcbi.1006775.","DOI":"10.1371\/journal.pcbi.1006775"},{"key":"1039_CR19","doi-asserted-by":"publisher","unstructured":"Schirm S, Engel C, Loeffler M, Scholz M: A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration. PLoS One 2013, 8(6):e65630.https:\/\/doi.org\/https:\/\/doi.org\/10.1371\/journal.pone.0065630.","DOI":"10.1371\/journal.pone.0065630"},{"issue":"9584","key":"1039_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342\u201350 http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673607611659.","journal-title":"Lancet"},{"issue":"4","key":"1039_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124(4):511\u20138 http:\/\/www.bloodjournal.org\/content\/bloodjournal\/124\/4\/511.full.pdf.","journal-title":"Blood"},{"issue":"3","key":"1039_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Kloess M, Schmits R, Feller AC, R\u00fcbe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634\u201341 http:\/\/www.bloodjournal.org\/content\/bloodjournal\/104\/3\/634.full.pdf.","journal-title":"Blood"},{"key":"1039_CR23","doi-asserted-by":"publisher","unstructured":"Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M: Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin\u2019s lymphoma: results from the NHL-B trial of the German high-grade non-Hodgkin\u2019s lymphoma study group (DSHNHL). Ann Oncol 2003, 14(6):881\u2013893.https:\/\/doi.org\/https:\/\/doi.org\/10.1093\/annonc\/mdg249.","DOI":"10.1093\/annonc\/mdg249"},{"key":"1039_CR24","doi-asserted-by":"publisher","unstructured":"Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S: Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Informatics Decis Mak 2008, 8(1):6.https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/1472-6947-8-6.","DOI":"10.1186\/1472-6947-8-6"},{"key":"1039_CR25","doi-asserted-by":"publisher","unstructured":"Lin H-C, Wu H-C, Chang C-H, Li T-C, Liang W-M, Wang J-YW: Development of a real-time clinical decision support system upon the web mvc-based architecture for prostate cancer treatment. BMC Med Informatics Decis Mak 2011, 11(1):16.https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/1472-6947-11-16.","DOI":"10.1186\/1472-6947-11-16"},{"key":"1039_CR26","doi-asserted-by":"publisher","unstructured":"Bucur A, van Leeuwen J, Christodoulou N, Sigdel K, Argyri K, Koumakis L, Graf N, Stamatakos G: Workflow-driven clinical decision support for personalized oncology. BMC Med Informatics Decis Mak 2016, 16(2):87.https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/s12911-016-0314-3.","DOI":"10.1186\/s12911-016-0314-3"},{"key":"1039_CR27","doi-asserted-by":"publisher","unstructured":"Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P et al: Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet 2017, 49:332.http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1038\/ng.3756.","DOI":"10.1038\/ng.3756"},{"key":"1039_CR28","doi-asserted-by":"publisher","unstructured":"Hamberg A-K, Hellman J, Dahlberg J, Jonsson EN, Wadelius M: A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. BMC Med Informatics Decis Mak 2015, 15(1):7.https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/s12911-014-0128-0.","DOI":"10.1186\/s12911-014-0128-0"},{"key":"1039_CR29","doi-asserted-by":"publisher","unstructured":"Shi H, Lyons-Weiler J: Clinical decision modeling system. BMC Med Informatics Decis Mak 2007, 7(1):23.https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/1472-6947-7-23.","DOI":"10.1186\/1472-6947-7-23"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-020-1039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12911-020-1039-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-020-1039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:26:59Z","timestamp":1612834019000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-020-1039-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1186\/s12911-020-1039-x","relation":{},"ISSN":["1472-6947"],"issn-type":[{"type":"electronic","value":"1472-6947"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"8 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. Although the shown clinical data is structurally identical to data from clinical trials, we linked different sets of clinical data to artificially created personal data. The created set of artificial patient data are used to illustrate the framework functionality only.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests related to the presented work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}